RxDoctor Payments Data

Christopher Carter, MD

Family Medicine · Bentonville, ARNPI 1962766840

Payments from drug & device makers

$7,550in general payments, 2019–2025

Across 486 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$828
  • AbbVie$778
  • GSK$751
  • AstraZeneca$625
  • Boehringer Ingelheim$604
  • Amgen$560
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$7,550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,550 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$116,914
Medicare patients
336
Services billed
1,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$165,135
EliquisApixaban121$139,817
JardianceEmpagliflozin86$85,178
MounjaroTirzepatide56$62,426
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$52,516
FarxigaDapagliflozin Propanediol27$36,841
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$34,964
XareltoRivaroxaban23$24,825
EntrestoSacubitril/Valsartan19$21,579
Breo ElliptaFluticasone/Vilanterol30$15,909
LinzessLinaclotide13$14,103
MyrbetriqMirabegron22$14,087
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,216
Atorvastatin Calcium635$5,881
Gabapentin164$5,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$523$165,135142 claims
PfizerEliquis$828$139,817121 claims
Boehringer IngelheimJardiance$604$85,17886 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$751$77,641100 claims
AstraZenecaFarxiga, Breztri Aerosphere$625$71,80575 claims
Lilly USA, LLCMounjaro$467$62,42656 claims
Johnson & JohnsonXarelto$16$24,82523 claims
NovartisEntresto$20$21,57919 claims
AbbVieLinzess, Synthroid$778$16,14546 claims
Astellas Pharma US IncMyrbetriq$269$14,08722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →